| Literature DB >> 28336883 |
Marianne Geiser1, Natalie Jeannet2, Martin Fierz3, Heinz Burtscher4.
Abstract
The number of daily products containing nanoparticles (NP) is rapidly increasing. NP in powders, dispersions, or sprays are a yet unknown risk for incidental exposure, especially at workplaces during NP production and processing, and for consumers of any health status and age using NP containing sprays. We developed the nano aerosol chamber for in vitro toxicity (NACIVT), a portable instrument for realistic safety testing of inhaled NP in vitro and evaluated effects of silver (Ag) and carbon (C) NP-which belong to the most widely used nanomaterials-on normal and compromised airway epithelia. We review the development, physical performance, and suitability of NACIVT for short and long-term exposures with air-liquid interface (ALI) cell cultures in regard to the prerequisites of a realistic in vitro test system for inhalation toxicology and in comparison to other commercially available, well characterized systems. We also review doses applied to cell cultures in vitro and acknowledge that a single exposure to realistic doses of spark generated 20-nm Ag- or CNP results in small, similar cellular responses to both NP types and that cytokine release generally increased with increasing NP dose.Entities:
Keywords: 3R; NACIVT; aerosol; air-liquid interface; airway epithelia; electrostatic deposition; engineered nanoparticles; in vitro; nanoparticles; toxicology
Year: 2017 PMID: 28336883 PMCID: PMC5333034 DOI: 10.3390/nano7020049
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Nano Aerosol Chamber for In Vitro Toxicity (NACIVT). (A) Picture of chamber with dedicated laptop and LabVIEW software; (B) schematic section showing and describing the main parts of the chamber.
Figure 2Particle delivery by electrostatic precipitation. Schematic section of an aerosol delivery tube, its Transwell® insert and the insert-holder plate, demonstrating the aerosol flow and particle deposition on the cell culture. In this schematic, particles are previously charged by a unipolar diffusion charger.
Characterization of the Nano Aerosol Chamber for In Vitro Toxicity (NACIVT) [38].
| Parameter | PSL, 200 nm | AgNP, 20 nm | Cell Type |
|---|---|---|---|
| Aerosol conditioning | |||
| Relative humidity * (%) | 85–95 | 85–95 | |
| Temperature * (°C) | 37 | 37 | |
| CO2 * (%) | 5 | 5 | |
| Aerosol flow per insert (mL/min) | 25 | 25 | |
| Particle distribution on Transwell® inserts | Even, singlets | Even, singlets | No cells |
| Deposition efficiency (%) | 15 | 40 | No cells |
| Particle-cell contact | |||
| CLSM | p-uptake | n.d. | Macs, BEAS-2B |
| ICP-MS | n.d. | 2/3 assoc. with cells | HBE, BEAS-2B |
| Cytotoxicity # (%) | |||
| Particles pipetted | <0.5 | n.d. | BEAS-2B |
| P-free air | <0.5 | n.d. | BEAS-2B |
| Exposed to aerosol | <0.5 | n.d. | BEAS-2B |
*: Adjustable and constant over time. PSL: polystyrene Latex particles, 200 nm in diameter, aerosol generation by nebulization; AgNP: silver nanoparticles, 20 nm in diameter, aerosol generation by spark ignition. #: Measured at 24 h after one hour of treatment, % difference to unexposed control. CLSM: Confocal laser scanning microscopy; ICP-MS: Induction coupled plasma mass spectrometry; P-free: Particle free; P-uptake: Particle uptake; BEAS-2B: Human bronchial epithelial cell line; Macs: Macrophages; HBE: Human bronchial epithelia; n.d.: Not done.
Figure 3Experimental setup for deposition efficiency measurements with fluorescent polystyrene latex particles (PSL) [38]. (A) Nebulizer and (B) silica gel dryer for aerosol generation; (C,D) Instruments for SMPS—particle sizing; (E) NACIVT chamber for cell exposure at air-liquid interface; and (F) chamber-controlling laptop with a LabVIEW based program (National Instruments Switzerland GmbH, Ennetbaden, Switzerland).
Physical performance of NACIVT in comparison to other aerosol deposition chambers for exposures of ALI cell cultures *.
| Parameter | NACIVT [ | Cultex® RFS/RFS compact [ | VITROCELL® [ |
|---|---|---|---|
| Cell exposure | |||
| Number of cell cultures | 24 | 3/6 in radial order around system inlet | 6/12/24/48 |
| Diameter of inserts (mm) | 6.5 | 6.5/12/24/35 (Petri dish) | 6.5/12/24/35 (Petri dish) |
| special adapters | special adapters | ||
| Cell cultures separated from each other | Yes | Yes | Yes |
| Duration of exposures (h) | °24 | °24 | °24 |
| Aerosol flow per insert (mL/min) | 25, adjustable | 5, 30, adjustable, separately for each chamber | 2, 5, 100, adjustable, separately for each chamber |
| Temperature and control | On-line, temperature sensors within the chamber, adjustable from computer via LabVIEW | 37 °C by temperature-controlled water flow (RFS) | 37 °C by temperature-controlled water flow. Automatic temperature control by sensors |
| On-line, temperature sensors within one chamber, adjustable (RFS Compact) | |||
| Particle deposition | |||
| Thermophoresis | No | No | Per extension kit |
| Electrostatic deposition | Switchable, bipolar, or unipolar charger | Can be added, unipolar charger | None |
| Electrical field | Up to 2 kV/insert, adjustable, both polarities DC or AC | 40–450 kV/m, adjustable | ±1.500 V, adjustable |
| Deposited dose | Aerosol electrometer, online | Gravimetric (precision balance) | Microbalance sensor, online photometer |
| Particle-free air control | Particle filter in-line before aerosol enters chamber | Parallel exposure of three inserts to test substance and three inserts to particle free air within one system | Independent clean air control modules or clean air positions in exposure module. |
| Concept of chamber | All-in-one | Modular | All-in-one or modular, automated exposure stations |
| Connectability to aerosol sources/generators | No restriction | No restriction | No restriction |
| Portable | Yes | Yes | Turnkey setups which can be moved to various locations |
*: Exposure systems with continuous delivery of aerosols to cells and with declaration of physical performance were considered.
Figure 4Morphology of in vitro differentiated human bronchial epithelia. (A) Light microscopic image exhibiting pseudostratified epithelium with basal (BC), ciliated (CC), and secretory (SC) cells; (B) transmission; and (C) scanning electron micrographs showing apical cell differentiations (cilia and microvilli) and junctional complexes (arrow heads in B).
Summary of changes in biomarkers in response to NP exposure showing the main contrast to the respective unexposed controls.
| NP Type | Cell Model | LDH | Caspase-3 | IL-6 | IL-8 | MCP-1 | Epithelial Integrity |
|---|---|---|---|---|---|---|---|
| Ag | CF HBE | + | = | = | + | − | = |
| Normal HBE | (−) | = | = | (+) | = | = | |
| BEAS-2B | − | = | = | = | = | = | |
| C | CF HBE | + | = | = | = | = | = |
| Normal HBE | = | = | + | + | (+) | = | |
| BEAS-2B | + * | = | + | + | + | = |
+: significant (p < 0.05) increase, in parenthesis not significant (p > 0.05). −: significant (p < 0.05) decrease, in parenthesis not significant (p > 0.05). = no response. *: values of control cultures were also high; NP: Nanoparticles; LDH: Lactate dehydrogenase; IL: Interleukin; MCP: Monocyte chemotactic protein; Ag: Silver; C: Carbon; CF: Cystic fibrosis; HBE: Human bronchial epithelia; BEAS-2B: Human bronchial epithelial cell line.
Detailed data of changes in biomarkers in response to NP exposure.
| NP Type | Cell Model | LDH % | Caspase-3 rfu/μg | IL-6 pg/mL | IL-8 pg/mL | MCP-1 pg/mL | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ctrl | D-1 | D-2 | D-3 | Ctrl | D-1 | D-2 | D-3 | Ctrl | D-1 | D-2 | D-3 | Ctrl | D-1 | D-2 | D-3 | Ctrl | D-1 | D-2 | D-3 | ||
| Ag | CF HBE | 8.7 | 23.1 # | 18.2 # | 14.4 # | 46.9 | 85.0 # | 34.1 | 54.4 # | 134.3 | 118.4 | 155.4 | 189.3 | 4923 | 8550 # | 7640 | 9967 # | 19.6 | 16.0 | 11.8 | 11.6 # |
| Normal HBE | 17.6 | 14.1 | 14.9 | 11.7 # | 20.7 | 39.6 | 18.7 | 13.1 | 29.2 | 36.1 | 29.5 | 50.9 | 4593 | 6955 | 5504 | 7339 | 4.5 | 2.4 | 2.9 | 2.0 | |
| BEAS-2B | 12.8 | 8.9 # | 12.3 | 8.4# | 162.3 | 84.8 | 133.5 | 199.5 | 63.4 | 64.1 | 76.3 | 57.5 | 169.1 | 242.7 # | 146.0 | 162.6 | 1298 | 1101 | 1573 | 1665 # | |
| C | CF HBE | 8.7 | 15.6 # | 16.8 # | 14.8 # | 46.9 | 67.6 | 53.5 | 40.8 | 134.3 | 117.4 | 156.0 | 134.3 | 4923 | 5651 | 7394 | 5017 | 19.6 | 16.8 | 20.8 | 22.5 |
| Normal HBE | 17.6 | 15.8 | 19.9 | 16.5 | 20.7 | 29.6 | 34.8 | 22.0 | 29.2 | 99.4 | 79.4 | 96.4 | 4593 | 8571 | 9992 # | 7697 | 4.5 | 5.1 | 5.4 | 13.1 # | |
| BEAS-2B | 12.8 | 12.0 | 12.0 | 25.7 # | 162.3 | 127.1 | 90.0 | 393.4 # | 63.4 | 159.5 # | 129.8 # | 151.9 # | 169.1 | 246.4 # | 221.3 # | 225.7 # | 1298 | 1791 # | 1799 # | 2005 # | |
Data are presented as mean values and SD. NP: Nanoparticles; LDH: Lactate dehydrogenase; IL: Interleukin; MCP: Monocyte chemotactic protein; Ag: Silver; C: Carbon; CF: Cystic fibrosis; HBE: Human bronchial epithelia; BEAS-2B: Human bronchial epithelial cell line. Ctrl: particle-free air control, i.e., no NP deposited. Deposited dose: Dose 1, D-1: 4 × 107 AgNP/3.5 × 108 CNP; Dose 2, D-1: 4 × 108 AgNP/3.5 × 109 CNP; Dose 3, D-3: 4 × 109 AgNP/2 × 1010 CNP; # p < 0.05 to particle-free control.